biotech
Longeveron Inc (NASDAQ: LGVN) rallied another 50% on Thursday as investors continued to celebrate the positive update of its Lomecel-B study. Why is it significant for Longeveron stock?The biotech firm reported encouraging investigator data from the said Phase 2 trial on Tuesday. Lomecel-B is its candidate treatment for hypoplastic left heart syndrome (HLHS). Note that the ELPIS II study is still ongoing. Ram Kumar – the principal investigator of that clinical trial said in a press release today: Lomecel-B clinical data is highly encouraging and suggests it has the potential to be a new, addit...
Invezz
GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn’t been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company. GT Biopharma stock trading volume today$GTBP did not publish a press release or file with the Securities & Exchange Commission on Monday. None of the Wall Street analysts issued a bullish note on it either. Still, more than 20 million shares of the Nasdaq-listed firm have exchanged hands today as of writing. The daily trading volume is up massively from about 10,000 only on average. The massive rally ...
Invezz
CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing. CX-901 shows favourable safety profileThe PROBODY T-cell engager showed anti-cancer properties in a Phase 1a clinical study of patients with advanced pancreatic cancer. CX-904 has an adequate safety profile as well to be administered in an outpatient setting, as per the press release on Thursday. The data “opens broad new possibilities for T-cell engagers across many targets and cancer types”, Sean McCarthy – the chief executive of Cyt...
Invezz
Google DeepMind has introduced the third iteration of its groundbreaking artificial intelligence model, AlphaFold, aimed at enhancing the efficiency and precision of drug design and disease treatment. This latest development was announced in London on May 8, marking a significant step forward in the use of AI in molecular biology. Comprehensive mapping of life’s moleculesSince its initial breakthrough in 2020, where AlphaFold utilized AI to predict protein behaviors, the tool has evolved. The current version, developed in collaboration with Isomorphic Labs—both companies under the leadership o...
Invezz
The iShares Russell 2000 ETF (IWM) has continued to underperform its bigger rivals like the SPDR S&P 500 ETF (SPY) and the Invesco QQQ (QQQ) ETFs. It has risen by just 2.2% this year while the other two have soared by over 5%. This is a trend that has been going on for a long time as mega-cap companies like Apple, Amazon, Nvidia, and Alphabet have continued soaring. The Russell 2000 index is mostly made up of smaller companies with thinner balance sheets and profitability. IWM vs SPY vs QQQ ETFs Best-performing Russell 2000 ETF stocksStill, the index has had some of the best-performing compani...
Invezz
Ocugen (NASDAQ: OCGN) stock price has launched higher since last year, helped by the rising hopes that OCU400 will be approved by the Food and Drug Administration (FDA). The stock surged by over 378% from its lowest point in September and by 183% this year. OCU400 could be a gamechangerOcugen is a biotech company that gained popularity during the Covid-19 pandemic as it worked on OCU500, a Covid vaccine. At the time, its stock surged to a high of $17.46, giving it a market valuation of over $12 billion. Now, the focus among investors has turned to OCU400, a new drug that will treat a rare cond...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら